Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Remon

Showing results (61-70 of 184) with videos related to

Pageof 19
Sort By:
Oncotargets and Therapy|August 9, 2020
Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in ContextSneha Gullapalli, Jordi Remon, Lizza E L Hendriks, et al.
Journal of Thoracic Disease|June 29, 2018
Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patientsJordi Remon, Laura Mezquita, Jesús Corral, et al.
Cancer Treatment Reviews|June 26, 2021
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challengesKaushal Parikh, Lizza E L Hendriks, Paolo Bironzo, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patientMaria Gion, Jordi Remon, Caroline Caramella, et al.
Cancer Treatment Reviews|September 26, 2020
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history beginsJordi Remon, Lizza E L Hendriks, Andres F Cardona, et al.
Critical Reviews in Oncology/Hematology|July 2, 2013
Adjuvant treatment in resected non-small cell lung cancer: current and future issuesJordi Remon, Pilar Lianes, Susana Martínez, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 1, 2024
New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on <i>EGFR</i>-Mutant TumorsStephanie P L Saw, Xiuning Le, Lizza E L Hendriks, et al.
Cancer Treatment Reviews|January 2, 2013
Malignant mesothelioma: new insights into a rare diseaseJordi Remon, Pilar Lianes, Susana Martínez, et al.
Bulletin Du Cancer|June 14, 2020
[Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management]Clémence Basse, Aurelie Swalduz, Matteo Giaj Levra, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?Jordi Remon, Antonin Levy, Pawan Singh, et al.
Pageof 19

Showing results (61-70 of 184) with videos related to

Sort By:
Pageof 19
Oncotargets and Therapy|August 9, 2020
Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in ContextSneha Gullapalli, Jordi Remon, Lizza E L Hendriks, et al.
Journal of Thoracic Disease|June 29, 2018
Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patientsJordi Remon, Laura Mezquita, Jesús Corral, et al.
Cancer Treatment Reviews|June 26, 2021
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challengesKaushal Parikh, Lizza E L Hendriks, Paolo Bironzo, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patientMaria Gion, Jordi Remon, Caroline Caramella, et al.
Cancer Treatment Reviews|September 26, 2020
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history beginsJordi Remon, Lizza E L Hendriks, Andres F Cardona, et al.
Critical Reviews in Oncology/Hematology|July 2, 2013
Adjuvant treatment in resected non-small cell lung cancer: current and future issuesJordi Remon, Pilar Lianes, Susana Martínez, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 1, 2024
New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on <i>EGFR</i>-Mutant TumorsStephanie P L Saw, Xiuning Le, Lizza E L Hendriks, et al.
Cancer Treatment Reviews|January 2, 2013
Malignant mesothelioma: new insights into a rare diseaseJordi Remon, Pilar Lianes, Susana Martínez, et al.
Bulletin Du Cancer|June 14, 2020
[Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management]Clémence Basse, Aurelie Swalduz, Matteo Giaj Levra, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?Jordi Remon, Antonin Levy, Pawan Singh, et al.
Pageof 19